$8.49
Value $254M
QTTB and UNH stock compared: price, dividend, valuation and results, from SEC filings.
$8.49
Value $254M
$346.10
Value $314B
Q32 Bio (QTTB) has a market value of $254M and UnitedHealth (UNH) $314B. Over the last year, with dividends, QTTB moved +300.5% and UNH +14.9%. The P/E is 7.9 for QTTB and 19.8 for UNH. Dividend yield: QTTB none, UNH 2.62%.
The main figures of both. A bar only shows which number is larger, not which is better.
Market value
QTTB$254M
UNH$314B
UNH is 1,237 times QTTB
Revenue, 12 months
QTTB$54M
UNH$450B
UNH is 8,368 times QTTB
Net income, 12 months
QTTB$32M
UNH$15.9B
UNH is 492 times QTTB
Operating margin
QTTB31.5%
UNH5.3%
26.2 points apart
ROIC
QTTB31.8%
UNH11.3%
20.5 points apart
P/E
QTTB7.9
UNH19.8
UNH is 2.5 times QTTB
Dividend yield
QTTB0.0%
UNH2.6%
2.6 points apart
5-year return
QTTB-90.9%
UNH-13.9%
77.0 points apart
A fainter bar means a negative number. The 5-year return includes dividends.
Both start at 100 at the beginning of the period, so the lines show how much each changed. With dividends means each dividend buys more shares.
QTTB-90.9%
UNH-13.9%
| Period | QTTBWith dividends | UNHWith dividends |
|---|---|---|
| 1 year since November 19, 2025 | +300.5%Price +300.5% | +14.9%Price +12.0% |
| 3 years since November 20, 2023 | -15.0%-5.3% a yearPrice -15.0% | -31.1%-11.7% a yearPrice -35.3% |
| 5 years since November 19, 2021 | -90.9%-38.1% a yearPrice -90.9% | -13.9%-2.9% a yearPrice -21.4% |
Each cell: the total return with dividends, its yearly rate, and the price change alone. Before taxes and costs. Past returns do not predict future ones.
As on each company's page. A description, not a recommendation: no one figure says which is better.
QTTBQ32 BioUNHUnitedHealth
| Price | $8.49 | $346.10 |
|---|---|---|
| Market value | $254M | $314B |
| Enterprise value (EV) | – | $360B |
| P/E | 7.9 | 19.8 |
| P/E, 5-year median | – | 25.0 |
| P/B | 0.9 | 3.0 |
| EV/EBIT | – | 15.0 |
| Free cash flow yield | – | 7.3% |
| Revenue, 12 months | $54M | $450B |
|---|---|---|
| Net income, 12 months | $32M | $15.9B |
| Free cash flow, 12 months | -$20M | $22.8B |
| Earnings per share, 12 months | $1.08 | $17.52 |
| Revenue growth, year on year | – | 11.8% |
| Revenue growth a year, past | +81.9%over 5 years | +11.7%over 5 years |
| EPS growth a year, past | – | -3.8%over 5 years |
| Gross margin | – | 88.3% |
|---|---|---|
| Operating margin | 31.5% | 5.3% |
| Net margin | 55.5% | 3.5% |
| ROIC | 31.8% | 11.3% |
| ROE | 34.8% | 15.5% |
| Cash | $290M | $28.5B |
|---|---|---|
| Total debt | $8.6M | $74.3B |
| Net debt / EBITDA | -16.6 | 1.6 |
| Interest cover | – | 6.2× |
| Dividend yield | – | 2.6% |
|---|---|---|
| Dividend per share, 12 months | – | $9.06 |
| Dividend growth a year, past | – | +12.6%over 5 years |
| Buyback yield | – | 1.8% |
| Shareholder yield | – | 4.4% |
Last 12 months from the latest 10-Q and 10-K. Value, P/E and yields at today's price. A dash means the figure does not exist or did not pass our checks.
By market value, UnitedHealth ($314B) is about 1,236.5 times Q32 Bio ($254M), at today's prices.
Since November 19, 2021, QTTB's price moved -90.9% and UNH's -21.4%. With dividends: QTTB -90.9% (-38.1% a year), UNH -13.9% (-2.9% a year). Past returns do not predict future ones.
The dividend yield at today's price is none for Q32 Bio and 2.62% for UnitedHealth. Over the last twelve months they paid – and $9.06 per share.
At today's price, the P/E is 7.9 for QTTB and 19.8 for UNH. It is the share price over the last twelve months' earnings per share.
Over the last twelve months, the net margin was 55.5% for Q32 Bio and 3.5% for UnitedHealth, and the operating margin 31.5% and 5.3%. Revenue was $54M and $450B.
The page does not answer that and does not suggest buying or selling. It puts the two companies' numbers side by side, from their SEC filings, for you to read and form your own view. The decision depends on your goals and situation.
With each of the two, and with the largest in its sector.
The other pages on US stocks, free to read. On the company pages, the last three fiscal years are open to everyone, five with a free account, and every year with Ploutos Investor.
Descriptive data from SEC filings and market prices.